Ubiquitin-like protein modifications in prostate and breast cancer

被引:17
作者
Wu, Fangting [1 ]
Mo, Yin-Yuan [1 ]
机构
[1] So Illinois Univ, Dept Med Microbiol Immunol & Cell Biol, Springfield, IL 62794 USA
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2007年 / 12卷
关键词
posttranslational modification; ubiquitin-like protein; sumoylation; Ubc9; prostate cancer and breast cancer;
D O I
10.2741/2094
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Post-translational modifications by ubiquitin-like proteins have been implicated in the regulation of diverse cellular processes, including nuclear transport, transcription regulation, stress response and DNA repair. Ubiquitination is well characterized for its roles in regulating these cellular processes. As a newly identified member of ubiquitin-like proteins, the small ubiquitin-like modifier (SUMO) has received a great deal of attention for its functions distinct from ubiquitin. In particular, alterations of SUMO conjugation or sumoylation have been implicated in several human diseases, including cancer. Although little is known about the underlying mechanism of sumoylation-associated tumorigenesis, the modulation of nuclear receptor (NR)-mediated signaling pathways is likely to play a role in this aspect. NRs are a family of ligand dependent transcription factors which control cell growth and differentiation in many cell types, as well as during the development of cancer. In this review, we will discuss some basic aspects of sumoylation and how sumoylation modulates the NR-mediated gene expression, focusing on androgen receptor (AR) and estrogen receptor (ER), a key player in progression of prostate or breast cancer.
引用
收藏
页码:700 / 711
页数:12
相关论文
共 119 条
[91]   Sumoylation of topoisomerase I is involved in its partitioning between nucleoli and nucleoplasm and its clearing from nucleoli in response to camptothecin [J].
Rallabhandi, P ;
Hashimoto, K ;
Mo, YY ;
Beck, WT ;
Moitra, PK ;
D'Arpa, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (42) :40020-40026
[92]   SUMO-1 modification activates the transcriptional response of p53 [J].
Rodriguez, MS ;
Desterro, JMP ;
Lain, S ;
Midgley, CA ;
Lane, DP ;
Hay, RT .
EMBO JOURNAL, 1999, 18 (22) :6455-6461
[93]   SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting [J].
Rodriguez, MS ;
Dargemont, C ;
Hay, RT .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (16) :12654-12659
[94]   EBNA3C coactivation with EBNA2 requires a SUMO homology domain [J].
Rosendorff, A ;
Illanes, D ;
David, G ;
Lin, J ;
Kieff, E ;
Johannsen, E .
JOURNAL OF VIROLOGY, 2004, 78 (01) :367-377
[95]   Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3 [J].
Saitoh, H ;
Hinchey, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (09) :6252-6258
[96]   Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity [J].
Schmidt, D ;
Müller, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (05) :2872-2877
[97]   Nuclear and unclear functions of SUMO [J].
Seeler, JS ;
Dejean, A .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (09) :690-699
[98]  
SENTIS S, 2005, MOL ENDOCRINOL
[99]   Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription [J].
Shang, YF ;
Hu, X ;
DiRenzo, J ;
Lazar, MA ;
Brown, M .
CELL, 2000, 103 (06) :843-852
[100]   Formation of the androgen receptor transcription complex [J].
Shang, YF ;
Myers, M ;
Brown, M .
MOLECULAR CELL, 2002, 9 (03) :601-610